Our mission

Founded in 2021, Anewex Biotechnology develops and commercializes biological experiment reagents, recombinant proteins, antibodies, engineered cell lines, organoid lines through integration of bioinformatics, molecular biology, protein expression, purification techniques, gene cloning, microbiology and immunology, using novel high-throughput technologies.

Anewex is on target to be one of the leading suppliers of bio-reagents in the twenty first century and is committed to improving human health with a focus on the field of immunotherapy, specifically CAR-T/NK cell technologies based-on generating highly specific and potent monoclonal antibodies.


Our Leadership



Oncology research has been the driving force of her academic and personal development since she was an undergraduate student at the University of Medicine and Pharmacy at Ho Chi Minh city, the top health science university in Viet Nam. After graduation, in pursuing both work and research at the Oncology Hospital at Ho Chi Minh city (2006-2008), she dedicated herself to her future role as a medical researcher and sought to raise broader public awareness of the cancer problem. In 2008, she was chosen to pursue graduate studies at Hiroshima University at the Department of Oral Maxillofacial Pathobiology, Graduate School of Biomedical and Health Sciences, Hiroshima University, where biological behaviors of cancer at the genetic level was studied and used to guide therapy; the partnership between basic science and its clinical counterpart were integral to her future career as a medical scientist. As soon as she graduated Ph.D., in September 2011, she successfully competed for the Postdoctoral Fellowship of JSPS. From January 2014 to March 2022, she has been a staff of Hiroshima University. Besides head and neck cancer research, she has extended her research field to study liver cancer (hepatocellular carcinoma and cholangiocarcinoma), NAFLD, NASH, and preterm birth. She is extremely careful, thoughtful in her approach to scientific investigation, and very competent in the molecular biologic techniques required for the completion of her projects. she promoted and established best in vitro and in vivo practice protocols for many if not most of the laboratory techniques used in her previous laboratories.

A- Publications

(1) Oral squamous cell carcinoma and cultural oral risk habits in Vietnam. SL Priebe, J Aleksejūnienė, C Zed, S Dharamsi, NT Hong, Nguyen PT. International Journal of Dental Hygiene 8: 159-168, 2010 (peer-reviewed).

(2) N-cadherin expression is correlated with metastasis of spindle cell carcinoma of head and neck region. Nguyen PT, Kudo Y, Takata T. Journal of Oral Pathology and Medicine 40:77-82, 2011 (peer-reviewed).

(3) N-cadherin expression is involved in malignant behavior of head and neck cancer in relation to epithelial-mesenchymal transition. Nguyen PT, Kudo Y, Takata T. Histol Histopathol 26: 147-156, 2011 (peer-reviewed).

(4) The FGFR-1 inhibitor PD173074 induces mesenchymal-epithelial transition through transcription factor AP-1. Nguyen PT, Tsunematsu T, Yanagisawa S, Kudo Y, Miyauchi M, Kamata N and Takata T. British Journal of Cancer,109: 2248-58, 2013 (peer-reviewed)

(5) Roles of VEGF-Flt-1 signaling in malignant behaviors of oral squamous cell carcinoma. Subarnbhesaj A, Miyauchi M, Mikuriya A, Nguyen PT, Chanbora C, Ayunintyas NF, Fujita M, Niida S, Takata T. PLOS ONE,22: e0187092, 2017 (peer-reviewed)

(6) Bovine lactoferrin reverses programming of epithelial-to-mesenchymal transition in oral squamous cell carcinoma. Chea C, Miyauchi M, Inubushi T, Okamoto K, Haing S, Nguyen PT, Imanaka H, Takata T. Biochem Biophys Res Commun, 502:142-147, 2018 (peer-reviewed)

(7) Interaction between N-cadherin and decoy receptor-2 regulates apoptosis in head and neck cancer. Nguyen PT, Nguyen D, Chea C, Miyauchi M, Fujii M, Takata T. Oncotarget 9: 31516-31530, 2018 (peer-reviewed)

(8) Periostin Antisense Oligonucleotide Prevents Hepatic Steatosis and Fibrosis in Mice: A novel strategy for Nonalcoholic Steatohepatitis Treatment. Kobayashi T, Kanno K, Sugiyama A, Nguyen PT, Kishikawa N, Otani Y, Tazuma S. Hepatology, 68, 2018 (peer-reviewed).

(13) Protective effect of phosphatidylcholine on lysophosphatidylcholine-induced cellular senescence in cholangiocyte. Ohigashi T, Kanno K, Sugiyama A, Nguyen PT, Kishikawa N, Otani Y, Kobayashi T, Matsuo H, Tazuma S. J Hepatobiliary Pacreat Sci, 26(12), 568-577, 2019

(14) Molecular mechanism in which periostin induces hepatic steatosis in vivo and in vitro. Kobayashi T, Kanno K, Sugiyama A, Nguyen PT, Kishikawa N, Tazuma S. Hepatology, 2019

(15) Deoxycholic acid-Induced senescent hepatic stellate cell promote malignant behaviors of hepatocellular carcinogenesis. Nguyen PT, Kanno K, Kobayashi T, Tazuma S. Gastroenterology, 156(6), 2019 (peer-reviewed)

(16) Periostin antisense oligonucleotide prevents hepatic steatosis and fibrosis in a mouse model of non-alcoholic steatohepatitis. Kobayashi T, Kanno K, Nguyen PT, Sugiyama A, Ito M, Tazuma S. J of Gastroenterology and Hepatology, May 2020

(17) Senescent hepatic stellate cells caused by deoxycholic acid modulates malignant behavior of hepatocellular carcinoma. Nguyen PT, Kanno K, Ito M, Tazuma S. J of Cancer Res and Clin Oncology, Sep 2020


B- Research grants and awards

2000               Valedictorian, University of Medicine and Pharmacy at Ho Chi Minh city.

2000 – 2006      Received AUF (Agence Universitaire de la Francophonie) Scholarship

2006                Second prize for dissertation of DDS (Doctor of Dental Surgery) graduation with the topic “Oral cancer in young patients.”

2008 – 2011     Received Monbukagakusho-MEXT scholarship.

2011 – 2013     Received JSPS Postdoctoral Fellowship for Foreign Researchers.

2014               Young Investigators’ Award from Hiroshima University

2017 – 2018     Hiroshima University Grant for a young researcher

2019 – 2021     Grant-in-aid from Japan Society for Promotion Science (Early Career Scientists)

2021 – 2024     Grant-in-aid from Japan Society for Promotion Science (Early Career Scientists)